【摘要】：目的探討胸腔鏡治療胸腺瘤的安全性及中長期療效。方法回顧性分析2001年4月~2014年11月我科胸腔鏡治療胸腺瘤185例資料,并隨訪生存和復發(fā)情況。結果中轉開胸7例(3.8%),主要中轉開胸原因為腫瘤侵犯大血管(5例)。MasaokaⅠ期123例(66.5%),Ⅱ期37例(20.0%),Ⅲ期19例(10.3%),Ⅳ期6例(3.2%)。MasaokaⅠ、Ⅱ、Ⅲ、Ⅳ期的R0切除率分別為100%(123/123)、100%(37/37)、89.5%(17/19)、66.7%(4/6)。手術時間(136.5±51.6)min,中位出血量50 ml(10~2500 ml),術后帶管時間(3.2±1.8)d,術后住院時間(5.8±2.9)d。全組無圍手術期死亡,術后并發(fā)癥10例(5.4%)。隨訪167例(90.3%),中位隨訪時間44個月(3~174個月)。5年總生存率94.6%,10年總生存率89.3%。合并重癥肌無力45例中成功隨訪41例,完全緩解9例,部分緩解23例,總體緩解率78.0%(32/41)。結論胸腔鏡治療早期(MasaokaⅠ、Ⅱ期)及部分經(jīng)過選擇的晚期(MasaokaⅢ、Ⅳ期)胸腺瘤安全有效,且長期療效滿意。胸腔鏡胸腺擴大切除治療胸腺瘤合并重癥肌無力療效滿意。
[Abstract]:Objective to investigate the safety and long-term efficacy of thoracoscopy in the treatment of thymoma. Methods 185 cases of thymoma treated by thoracoscopy from April 2001 to November 2014 were retrospectively analyzed and their survival and recurrence were followed up. Results 7 cases (3.8%) were converted to thoracotomy. The main causes of conversion were tumor invasion of large vessels (123 cases (66.5%) in 5 cases of). Masaoka 鈪，

本文編號：2306403